Mirae Asset Global Investments Co. Ltd. Makes New $11.57 Million Investment in Waters Corporation $WAT

Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Waters Corporation (NYSE:WAT) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 26,338 shares of the medical instruments supplier’s stock, valued at approximately $11,573,000.

A number of other hedge funds have also made changes to their positions in the stock. ProShare Advisors LLC increased its holdings in Waters by 2.1% in the third quarter. ProShare Advisors LLC now owns 15,967 shares of the medical instruments supplier’s stock worth $7,016,000 after buying an additional 323 shares during the last quarter. Vise Technologies Inc. increased its position in shares of Waters by 87.7% during the third quarter. Vise Technologies Inc. now owns 2,059 shares of the medical instruments supplier’s stock valued at $905,000 after purchasing an additional 962 shares during the period. Modera Wealth Management LLC grew its stake in shares of Waters by 57.1% in the 3rd quarter. Modera Wealth Management LLC now owns 1,013 shares of the medical instruments supplier’s stock valued at $445,000 after purchasing an additional 368 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Waters during the third quarter worth about $177,000. Finally, North Dakota State Investment Board lifted its position in shares of Waters by 3.0% during the third quarter. North Dakota State Investment Board now owns 3,010 shares of the medical instruments supplier’s stock worth $1,323,000 after purchasing an additional 88 shares in the last quarter. 94.01% of the stock is owned by hedge funds and other institutional investors.

Waters Price Performance

Shares of NYSE:WAT opened at $467.99 on Thursday. The company’s 50-day moving average is $433.18 and its 200 day moving average is $371.53. Waters Corporation has a fifty-two week low of $282.77 and a fifty-two week high of $482.28. The company has a market capitalization of $45.98 billion, a P/E ratio of 200.86, a price-to-earnings-growth ratio of 2.67 and a beta of 1.16. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.29 and a current ratio of 0.66.

Waters (NYSE:WAT) last issued its earnings results on Tuesday, November 3rd. The medical instruments supplier reported $4.10 EPS for the quarter, topping analysts’ consensus estimates of $4.00 by $0.10. The company had revenue of $1.77 billion for the quarter, compared to analysts’ expectations of $1.75 billion. Waters had a net margin of 1.75% and a return on equity of 9.91%. The firm’s revenue was up 120.9% compared to the same quarter last year. During the same quarter last year, the company earned $3.40 EPS. On average, equities research analysts forecast that Waters Corporation will post 14.61 earnings per share for the current year.

Key Stories Impacting Waters

Here are the key news stories impacting Waters this week:

• Positive Sentiment: Q3 results topped expectations. Waters reported adjusted EPS of $4.10 versus about $4.00 expected and revenue of $1.77 billion versus $1.75 billion expected. Organic revenue grew 9% (10% in constant currency); reported revenue growth of 120.9% also reflected acquisitions. Waters Q3 results
• Positive Sentiment: Management raised its 2026 outlook and outlined growth beyond this year. The earnings-call framework pointed to high-single-digit growth and a 29.2% adjusted operating margin for 2027, reinforcing expectations for continued expansion. Earnings call highlights
• Positive Sentiment: Analysts raised targets after the results. Citi raised its target to $536 and kept a Buy rating; TD Cowen and Barclays moved to $530, while RBC set $525. These revisions signal improved confidence in Waters’ prospects. Citi analyst actions
• Positive Sentiment: MOBILion Systems acquisition expands Waters’ proteomics capabilities. Its ion-mobility technology complements Waters’ mass-spectrometry platform and is aimed at research workflows that need faster, higher-resolution data. MOBILion acquisition announcement
• Neutral Sentiment: JPMorgan lifted its price target to $470 but retained a Neutral rating, indicating less near-term upside in its view. JPMorgan analyst action
• Negative Sentiment: Valuation may limit further gains: the supplied market data puts WAT’s P/E at 116.71, and recent commentary has questioned whether the shares already reflect the improved outlook. Waters valuation commentary

Analysts Set New Price Targets

Several brokerages have commented on WAT. TD Cowen upped their target price on shares of Waters from $515.00 to $530.00 and gave the company a “buy” rating in a research note on Wednesday. Sanford C. Bernstein restated an “outperform” rating and set a $535.00 price objective on shares of Waters in a research note on Wednesday. Evercore upped their target price on shares of Waters from $410.00 to $480.00 in a report on Wednesday, October 7th. Weiss Ratings raised Waters from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Finally, Wall Street Zen upgraded Waters from a “hold” rating to a “buy” rating in a research note on Monday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $475.48.

Waters Company Profile

Waters Corporation (NYSE:WAT) develops and manufactures analytical technologies used to measure, identify and characterize chemical and biological substances. Its customers include pharmaceutical and biotechnology companies, industrial manufacturers, academic and government laboratories, and organizations involved in food, environmental and clinical testing.

The company’s product portfolio includes high-performance liquid chromatography and ultra-performance liquid chromatography systems, mass spectrometers, chromatography columns and consumables, and laboratory software for data management and analysis.